جزر

TAFFIC is a fixed dose combination product (three-drug) containing 50 mg of bictegravir (BIC), 200 mg of emtricitabine (FTC), and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of TAFFIC is one tablet taken orally once daily with or without food. TAFFIC is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to Bictegravir, Emtricitabine and Tenofovir Alafenamide.